State Street SPDR S&P Pharmaceuticals ETF XPH
68.82 USD +0.89 (+1.31%)
At closeNov 11, 2026, 4:00 PM EST
68.82 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
67.83 Day range 68.88
50.04 52-week range 74.35
- YTD
- +22.87%
- 1 year
- +34.81%
News
fool.com Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
fool.com Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with…
fool.com Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK? State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio but has a lower dividend yield than Simplify Health Care ETF. Simplify Health Care ETF has shown significantly lower maximum…
zacks.com Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now? The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
seekingalpha.com XPH: Healthcare Sector Dashboard For October Pharmaceuticals/biotechnology are currently overvalued by 14% versus 11-year averages, while healthcare equipment appears undervalued despite recent value score deterioration. State Street SPDR S&P…
fool.com Better Pharma ETF: iShares IHE vs. State Street XPH The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S.…
fool.com Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
zacks.com Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on…
zacks.com Execution of Pharma Tariffs Brings These ETFs Into Focus Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.
defenseworld.net SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Sees Large Volume Increase – Still a Buy? SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH - Get Free Report) shares saw an uptick in trading volume on Monday. 145,914 shares changed hands during mid-day trading, an increase of 46% from the…
defenseworld.net Integrated Wealth Concepts LLC Buys Shares of 48,874 SPDR S&P Pharmaceuticals ETF $XPH Integrated Wealth Concepts LLC purchased a new position in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) in the undefined quarter, according to the company in its most recent filing with the…
fool.com IXJ vs XPH: Global Healthcare ETF or Pharma Focus? iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered…
fool.com Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
fool.com Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
fool.com XPH vs PJP: Which Pharma ETF Offers Better Value The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more…
fool.com Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH The Invesco S&P 500 Equal Weight Health Care ETF provides broad exposure to the sector, while the State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry. The…
zacks.com Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now? The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
zacks.com Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)? Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of…
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
etftrends.com Healthcare Rules State Street's Top 5 ETFs in Past Month With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key…
fool.com Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year…
benzinga.com Why Is Organon Stock Skyrocketing Monday? Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news.
benzinga.com Why Is Amneal Pharmaceuticals Stock Gaining Today? Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
benzinga.com Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.
benzinga.com Prestige Bets $1 Billion On World's Most Iconic Nasal Strip Prestige Consumer Healthcare acquires Breathe Right brand for $1.045 billion. Deal expands OTC portfolio into sleep & breathing categories.
benzinga.com Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
benzinga.com Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
benzinga.com Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
benzinga.com Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
benzinga.com Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
benzinga.com Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
benzinga.com Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
benzinga.com Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe Trump announced 50% tariffs on all EU imports starting June 1, citing high trade deficits and unfair barriers. Pharmaceutical products and cars most exposed.
benzinga.com Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
benzinga.com Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
benzinga.com ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
benzinga.com Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
benzinga.com Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
benzinga.com Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 Perrigo Company shares surged after issuing financial targets for 2025 & 2025-2027 on investor day. Expect sales growth, EPS, and margin expansion. 'Three-S' plan will enhance cash flow & shareholder…
benzinga.com Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
benzinga.com Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local…
benzinga.com Organon Beats On Q1, Women's Health Leads the Charge Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
benzinga.com Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S.
benzinga.com Chevron, Uber Technologies, And A Way To 'Bet Against The Big Guys' Are CNBC's 'Final Trades' On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said that each name is around 3% in the SPDR S&P Pharmaceuticals ETF (ARCA: XPH). The pharma sector is a…
benzinga.com 3 Pharmaceutical ETFs That Could Be Due For A Rebound These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of buyers who have gathered around the same price level. At support…
benzinga.com Big Pharma In Canada Offers C$1B In Last Attempt To Stop Drug Pricing Crackdown The pharmaceutical industry has delivered a C$1 billion ($761 million) proposal to the Canadian government in an attempt to stave off an upcoming price crackdown, Reuters reported- benzinga.com 'Fast Money Halftime Report' Picks For September 25
benzinga.com Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff